尽管聚(ADP-核糖)聚合酶抑制剂(PARPis)和抗PDCD1抗体具有治疗潜力,但HRD的获得性耐药性和HRP患者的次优反应需要更精准的治疗。 2024年8月13日,复旦大学华克勤、韩晓、Qu Xinyu共同通讯在Advanced Science在线发表题为“Dissecting the Disti...
[2]National Cancer Institute.Cancer stat facts:ovarian cancer.National Cancer Institute Surveillance,Epidemiology,and End Results Program 2013–2019 https://seer.cancer.gov/statfacts/html/ovary.html(2019). [3]National Comprehensive...
4. Ray-Coquard, I et al. “Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.” Annals of oncology : official journal of the European Soci...
[2]DiSilvestro P, et al. SOLO1 Investigators. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J...
Edelson M, Reid T, Carlson J, Friedlander M. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over. Gynecol Oncol. 2024 Aug;187:2...
Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors Advanced science; IF: 14.300; DOI: 10.1002/advs.202309755 ...
[2]. 2022NCCN. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. [3]. 中国肿瘤整合诊疗指南(CACA):卵巢癌.https://cacaguidelines.cacakp.com/pdflist/detail?id=75 [4].2022ESMO. Analytical Performance of A...
3. How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes. Eur...
1、揭示HRD与HRP卵巢癌的独特肿瘤微环境:对靶向治疗耐药性与难治性的新启示 Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors Advanced science; IF: 14.300; DOI: ...
[1]Wen H, Feng Z, Ma Y T, et al. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer[J].BMC Cancer, 2022. [2] ATM B, FAM175A M. 上皮性卵巢癌 PAR...